Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ultragenyx (NASDAQ: RARE), Portola Pharma (NASDAQ: PTLA) and Emergent Biosolutions (NYSE: EBS)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx (NASDAQ: RARE), Portola Pharma (NASDAQ: PTLA) and Emergent Biosolutions (NYSE: EBS).

Ultragenyx (NASDAQ: RARE)

Piper Jaffray analyst Steven Breazzano reiterated a Buy rating on Ultragenyx (NASDAQ: RARE) yesterday and set a price target of $79. The company’s shares opened today at $61.17.

According to TipRanks.com, Breazzano is a 1-star analyst with an average return of -6.2% and a 54.5% success rate. Breazzano covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Mirati Therapeutics, and Bavarian Nordic A/S.

Currently, the analyst consensus on Ultragenyx is Strong Buy and the average price target is $97.25, representing a 59.0% upside.

In a report issued on November 4, Canaccord Genuity also reiterated a Buy rating on the stock with a $120 price target.
Portola Pharma (NASDAQ: PTLA)

In a report released yesterday, Phil Nadeau from Cowen & Co. reiterated a Buy rating on Portola Pharma (NASDAQ: PTLA), with a price target of $40. The company’s shares opened today at $16.25, close to its 52-week low of $15.68.

Nadeau said:

“PTLA reported a net loss of $93MM and had $275MM in cash at the end of 9/30.”

According to TipRanks.com, Nadeau is a 1-star analyst with an average return of -1.7% and a 39.1% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Portola Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $30.

Emergent Biosolutions (NYSE: EBS)

In a report released yesterday, Eric Schmidt from Cowen & Co. reiterated a Hold rating on Emergent Biosolutions (NYSE: EBS), with a price target of $33. The company’s shares opened today at $27.80.

Schmidt observed:

“Emergent BioSolutions reported Q3 revenue ($143MM vs. $113MME) and net income.”

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 14.2% and a 46.7% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Emergent Biosolutions has an analyst consensus of Moderate Buy, with a price target consensus of $37.